CTSS and breast carcinoma: The expression of at least one of the main cysteine cathepsins, B, L and S in all breast tumor tissues tested—together with the previously reported low cathepsin levels in normal breast tissue – indicates that cathepsin-activatable imaging agents with broad reactivity for these three proteases will likely be effective in the vast majority of breast cancer patients, regardless of molecular subtype and treatment status.